About Alector
Alector is a company based in San Francisco (United States) founded in 2013. Alector has raised $214.78 million across 6 funding rounds from investors including AbbVie, New Leaf Venture Partners and HHS. The company has 211 employees as of December 31, 2022. Alector offers products and services including AL101/GSK4527226 and Pipeline Therapies. Alector operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
- Employees 211 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alector, Inc.
-
Annual Revenue
$100.56 M (USD)3.6as on Dec 31, 2024
-
Net Profit
-$119.05 M (USD)8.7as on Dec 31, 2024
-
EBITDA
-$133.95 M (USD)6.26as on Dec 31, 2024
-
Total Equity Funding
$214.78 M (USD)
in 6 rounds
-
Latest Funding Round
$133 M (USD), Series E
Jul 25, 2018
-
Investors
AbbVie
& 19 more
-
Employee Count
211
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alector
Alector is a publicly listed company on the NASDAQ with ticker symbol ALEC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alector
Alector offers a comprehensive portfolio of products and services, including AL101/GSK4527226 and Pipeline Therapies.
Drug for early Alzheimer's disease treatment in clinical trials.
Candidates targeting FTD and ALS for disease modification.
People of Alector
Unlock access to complete
Leadership Team
24 people
Software Development Team
17 people
Scientific Team
8 people
Finance and Accounting
7 people
Senior Team
5 people
Product Management Team
5 people
Data Analysis and Operations Team
5 people
Operations Team
5 people
Unlock access to complete
Funding Insights of Alector
Alector has successfully raised a total of $214.78M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $133 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alector
Alector has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, New Leaf Venture Partners and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked |
Investor details for Alector
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alector
Investment portfolio details for Alector
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alector
Detailed financials for Alector
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alector Comparisons
Peer comparison for Alector
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alector
Alector operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Alector
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alector
Complete news archive for Alector
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alector
Alector was founded in 2013.
Alector is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Alector is a funded company, having raised a total of $214.78M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Alector is 211.
Annual revenue of Alector is $100.56M as on Dec 31, 2024.
Alector was founded in 2013 and is headquartered in San Francisco, United States. Immuno-modulatory therapies targeting dementia and other neurodegenerative disorders are developed by the company. Antibody drugs engaging neuro-immune targets validated genetically are included in the pipeline. Drug candidates such as AL001 for dementia, AL101 for neurology, AL002 and AL003 for Alzheimers, AL014 for Alzheimers, and AL008 for oncology are advanced. Operations focus on biotechnology within the healthcare sector.
Alector's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Alector offers AL101/GSK4527226 and Pipeline Therapies.
Yes, Alector is publicly traded on NASDAQ under the ticker symbol ALEC.
Alector has 20 investors. Key investors include AbbVie, New Leaf Venture Partners, HHS, Orbimed, and Perceptive Advisors.
The ticker symbol of Alector is ALEC on NASDAQ.